The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma
Abstract
Purpose: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) by retroviral-mediated gene transfer generates potent antitumor immunity in patients with metastatic melanoma. Further clinical development of this immunization scheme requires simplification of vaccine manufacture. We conducted a phase I clinical trial testing the biologic activity of vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer. Patients and Methods: Excised metastases were processed to single cells, transduced with a replication-defective adenoviral vector encoding GM-CSF, irradiated, and cryopreserved. Individual vaccines were composed of 1 × 10 6, 4 × 10 6, or 1 × 10 7 tumor cells, depending on overall yield, and were injected intradermally and subcutaneously at weekly and biweekly intervals. Results: Vaccines were successfully manufactured for 34 (97%) of 35 patients. The average GM-CSF secretion was 745 ng/10 6 cells/24 hours. Toxicities were restricted to grade 1 to 2 local skin reactions. Eight patients were withdrawn early because of rapid disease progression. Vaccination elicited dense dendritic cell, macrophage, granulocyte, and lymphocyte infiltrates at injection sites in 19 of 26 assessable patients. Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, dissociated, autologous, nontransduced tumor cells in 17 of 25 patients. Metastatic lesions that were resected after vaccination showed brisk or focal T-lymphocyte and plasma cell infiltrates with tumor necrosis in 10 of 16 patients. One complete, one partial, and one mixed response were noted. Ten patients (29%) are alive, with a minimum follow-up of 36 months; four of these patients have no evidence of disease. Conclusion: Vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Self-citationRosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
The Basic Science of Gene Therapy
Mulligan, R. C. (1993) · Science · doi:10.1126/science.8493530 · Cited by 1,741
Self-citationModel Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1669 · Cited by 1,226
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
Self-citationRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Human neoplasms elicit multiple specific immune responses in the autologous host.
Sahin, U., Türeci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., & Pfreundschuh, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11810 · Cited by 1,078
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Self-citationHuman tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Banchereau, J., Palucka, A. K., Dhodapkar, M. V., Burkeholder, S. B., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., et al. (2001) · PubMed · Cited by 806
Construction of adenovirus vectors through Cre-lox recombination
Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., & Phipps, M. L. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1842-1849.1997 · Cited by 789
Self-citationMarchand, M., van Baren, N., Weynants, P., Brichard, V., Dr�no, B., Tessier, M.-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s · Cited by 784
Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism
Cullen, B. R. (1986) · Cell · doi:10.1016/0092-8674(86)90696-3 · Cited by 681
Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13141 · Cited by 571
Self-citationRomero, P., Rod Dunbar, P., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J.-L., Liénard, D., Cerottini, J.-C., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1641 · Cited by 521
Livingston, P. O., Wong, G. Y., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., & Ritter, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1036 · Cited by 516
New Paths in Human Cancer Serology
Old, L. J., & Chen, Y.-T. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1163 · Cited by 446
Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.-T., Ritter, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413497 · Cited by 426
Mach, N., Gillessen, S., Wilson, S. B., Sheehan, C., Mihm, M. C., & Dranoff, G. (2000) · PubMed · Cited by 410
Self-citationMORTON, D. L., FOSHAG, L. J., HOON, D. S. B., NIZZE, J. A., WANEK, L. A., CHANG, C., DAVTYAN, D. G., GUPTA, R. K., ELASHOFF, R., & IRIE, R. F. (1992) · Annals of Surgery · doi:10.1097/00000658-199210000-00010 · Cited by 403
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
Jäger, E., Nagata, Y., Gnjatic, S., Wada, H., Stockert, E., Karbach, J., Dunbar, P. R., Lee, S. Y., Jungbluth, A., Jäger, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4760 · Cited by 398
Mihm, M. C., Clemente, C. G., & Cascinelli, N. (1996) · PubMed · Cited by 318
Self-citationSalgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F. S., Jaklitsch, M., Mentzer, S., Swanson, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.091 · Cited by 296
Self-citationLee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuge, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3836 · Cited by 244
Slingluff, C. L., Yamshchikov, G. V., Neese, P. Y., Galavotti, H., Eastham, S., Engelhard, V. H., Kittlesen, D. J., Deacon, D. H., Hibbitts, S., Grosh, W. W., et al. (2001) · PubMed · Cited by 229
Wang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S. G., & Weber, J. S. (1999) · PubMed · Cited by 219
A New Immunologic Marker for Human Langerhans Cells
Murphy, G. F., Bhan, A. K., Sato, S., Mihm, M. C., & Harrist, T. J. (1981) · New England Journal of Medicine · doi:10.1056/nejm198103263041320 · Cited by 210
Self-citationZeng, G., Wang, X., Robbins, P. F., Rosenberg, S. A., & Wang, R.-F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061507398 · Cited by 193
Active-specific immunotherapy for melanoma.
Mitchell, M. S., Harel, W., Kempf, R. A., Hu, E., Kan-Mitchell, J., Boswell, W. D., Dean, G., & Stevenson, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.856 · Cited by 184
Reilly, R. T., Machiels, J.-P., Emens, L. A., Ercolini, A. M., Okoye, F. I., Lei, R. Y., Weintraub, D., & Jaffee, E. M. (2001) · PubMed · Cited by 151
Clinical cancer vaccine trials
Jäger, E., Jäger, D., & Knuth, A. K. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00318-7 · Cited by 131
Cytokine-secreting tumor cell vaccines
Mach, N., & Dranoff, G. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00144-8 · Cited by 115
Self-citationBorrello, I., Sotomayor, E. M., Cooke, S., & Levitsky, H. I. (1999) · Human Gene Therapy · doi:10.1089/10430349950017347 · Cited by 108
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction
Schmollinger, J. C., Vonderheide, R. H., Hoar, K. M., Maecker‐Kolhoff, B., Schultze, J. L., Hodi, F. S., Soiffer, R. J., Jung, K., Kuroda, M. J., Letvin, N. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530311100 · Cited by 105
Self-citationYu, J. S., Burwick, J. A., Dranoff, G., & Breakefteld, X. O. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.9-1065 · Cited by 92
Self-citationAnichini, A., Mortarini, R., Maccalli, C., Squarcina, P., Fleischhauer, K., Mascheroni, L., & Parmiani, G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.208 · Cited by 91
Dranoff, G., Soiffer, R. J., Lynch, T. J., Mihm, M. C., Jung, K., Kolesar, K., Liebster, L., Lam, P., Duda, R. B., Mentzer, S. J., et al. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.1-111 · Cited by 71
Self-citation
Cited by
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Management of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 855
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Metadata
- Authors
- Soiffer, R., Hodi, F. S., Haluska, F., Jung, K., Gillessen, S., Singer, S., Tanabe, K., Duda, R., Mentzer, S., Jaklitsch, M., Bueno, R., Clift, S., Hardy, S., Neuberg, D., Mulligan, R., Webb, I., Mihm, M., & Dranoff, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-09-01
- Volume
- 21
- Issue
- 17
- Pages
- 3343-3350
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112897941
- Cited by
- 305
- References
- 39
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.